DISCOUNT ZERTIFIKAT - BRISTOL-MYERS SQUIBB | Market Closed - Boerse Frankfurt Warrants 02:03:15 2024-06-14 pm EDT | ||
| 37.65 EUR | +0.16% |
|
| Current month | +2.56% | ||
| 1 month | -5.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 37.65 | +0.16% |
| 24-06-13 | 37.59 | -1.75% |
| 24-06-12 | 38.26 | -1.11% |
| 24-06-11 | 38.69 | +1.39% |
| 24-06-10 | 38.16 | +3.19% |
Real-time Boerse Frankfurt Warrants
Last update June 14, 2024 at 02:03 pm EDT
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VM79XT |
| ISIN | DE000VM79XT2 |
| Date issued | 2024-01-10 |
| Maturity | 2024-12-20 (188 Days) |
| Parity | 1 : 1 |
| Emission price | 44.86 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 47.3 € |
|---|---|
| Lowest since issue | 36.06 € |
| Spread | 0.06 € |
| Spread % | 0.16% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2
USD
Average target price
53.19
USD
Spread / Average Target
+29.11%
- Stock Market
- Certificates
- Certificat
